Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127869141 | 12786914 | 1 | I | 20160704 | 20160914 | 20160928 | 20160928 | EXP | US-TEVA-694476USA | TEVA | 0.00 | F | Y | 108.80000 | KG | 20160928 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127869141 | 12786914 | 1 | PS | MONTELUKAST SODIUM. | MONTELUKAST SODIUM | 1 | Unknown | 10 MILLIGRAM DAILY; | 78605 | 10 | MG | QD | |||||||
| 127869141 | 12786914 | 2 | SS | GABAPENTIN. | GABAPENTIN | 1 | Unknown | Y | 76017 | QD | |||||||||
| 127869141 | 12786914 | 3 | SS | GABAPENTIN. | GABAPENTIN | 1 | Unknown | Y | 76017 | ||||||||||
| 127869141 | 12786914 | 4 | SS | ALBUTEROL. | ALBUTEROL | 1 | Unknown | 0 | 180 | UG | INHALANT | ||||||||
| 127869141 | 12786914 | 5 | SS | EYLEA | AFLIBERCEPT | 1 | Intraocular | .2 MILLIGRAM DAILY; | 0 | 2 | MG | INJECTION | |||||||
| 127869141 | 12786914 | 6 | SS | EYLEA | AFLIBERCEPT | 1 | Intraocular | .2 MILLIGRAM DAILY; | 0 | 2 | MG | INJECTION | |||||||
| 127869141 | 12786914 | 7 | SS | EYLEA | AFLIBERCEPT | 1 | Intraocular | .2 MILLIGRAM DAILY; | 0 | 2 | MG | INJECTION | |||||||
| 127869141 | 12786914 | 8 | SS | SYMBICORT | BUDESONIDEFORMOTEROL FUMARATE DIHYDRATE | 1 | Respiratory (inhalation) | 20 MICROGRAM DAILY; 160/4.5 MCG 2 INHALATIONS | 0 | 10 | UG | BID | |||||||
| 127869141 | 12786914 | 9 | SS | ZYRTEC | CETIRIZINE HYDROCHLORIDE | 1 | 10 MILLIGRAM DAILY; | 0 | 10 | MG | QD | ||||||||
| 127869141 | 12786914 | 10 | SS | FLONASE | FLUTICASONE PROPIONATE | 1 | Nasal | 0 | |||||||||||
| 127869141 | 12786914 | 11 | SS | SPIRIVA RESPIMAT | TIOTROPIUM BROMIDE | 1 | 0 | QD | |||||||||||
| 127869141 | 12786914 | 12 | SS | AZELASTINE HYDROCHLORIDE. | AZELASTINE HYDROCHLORIDE | 1 | Nasal | 0 | |||||||||||
| 127869141 | 12786914 | 13 | C | Losartan/ HCTZ (Hydrochlorothiazide, Losartan Potassium) | 2 | 0 | |||||||||||||
| 127869141 | 12786914 | 14 | C | ZETIA | EZETIMIBE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127869141 | 12786914 | 1 | Product used for unknown indication |
| 127869141 | 12786914 | 2 | Spinal column stenosis |
| 127869141 | 12786914 | 4 | Product used for unknown indication |
| 127869141 | 12786914 | 5 | Neovascular age-related macular degeneration |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127869141 | 12786914 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127869141 | 12786914 | Asthma | |
| 127869141 | 12786914 | Drug ineffective | |
| 127869141 | 12786914 | Eosinophil count increased | |
| 127869141 | 12786914 | Pulmonary function test decreased | |
| 127869141 | 12786914 | Transient ischaemic attack |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127869141 | 12786914 | 2 | 201601 | 201602 | 0 | |
| 127869141 | 12786914 | 3 | 20160703 | 201607 | 0 | |
| 127869141 | 12786914 | 5 | 20160524 | 0 | ||
| 127869141 | 12786914 | 6 | 20160621 | 20160621 | 0 | |
| 127869141 | 12786914 | 7 | 20160719 | 20160719 | 0 |